Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors are right to wonder if this risky biotech has what it takes to develop a new coronavirus vaccine.

Should You Sell Ocugen Stock Right Now?

Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine

Ocugen Establishes Vaccine Scientific Advisory Board

Ocugen (OCGN) stock is continuing to rise higher on Wednesday following news yesterday concerning a vaccine for the novel coronavirus. The post OCGN Stock: 5 Things for Investors to Know as Ocugen Soars 100%+ appeared first on InvestorPlace.

OCGN Stock: 5 Things for Investors to Know as Ocugen Soars 100%+

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 173.88% today. This is why it happened.

Ocugen (OCGN) Stock Price Increases 173.88%: Why It Happened

Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares

Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares

OCGN stock is on the move Tuesday after Ocugen announced plans to commercialize and develop a Covid-19 vaccine. The post OCGN Stock: Why Ocugen Shares Are Soaring 130% Today appeared first on InvestorPlace.

OCGN Stock: Why Ocugen Shares Are Soaring 130% Today

Shares of Ocugen Inc (NASDAQ: OCGN), a micro-cap biopharma, gap-opened Tuesday's session higher and are trading with noteworthy gains. What Happened: Malvern, Pennsylvania-based Ocugen said it has signed a binding letter of intent to co-develop India-based Bharat Biotech's COVID-19 vaccine candidate codenamed Covaxin - an advanced stage whole-viron inactivated vaccine candidate - for use in the U.S. market.

Penny Stock Ocugen Rips Higher By 130% On Vaccine News

Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US

Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market

MALVERN, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will postpone its 2020 Annual Meeting of Stockholders to December 23, 2020 to provide its stockholders additional time to vote on the proposals submitted for stockholder approval at the meeting.

Ocugen Inc. Announces Plan to Postpone Annual Meeting of Stockholders

Ocugen (OCGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Ocugen (OCGN) Soars: Stock Adds 6.6% in Session

MALVERN, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), the nation's leading independent proxy advisory firms, have recommended that Ocugen stockholders vote “FOR” both Proposals 1 and 2 at the Company's Annual Meeting of Stockholders to be held on December 11, 2020.

Leading Independent Proxy Firms ISS and Glass Lewis Recommend Ocugen Stockholders Vote “FOR” Reverse Stock Split and Authorized Shares Amendment Proposals

MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy's Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish & Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy – Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&D.

CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy's Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies

Ocugen (OCGN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Ocugen (OCGN) Looks Good: Stock Adds 5.5% in Session

First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021 First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021

Ocugen Provides Business Update and Third Quarter 2020 Financial Results

MALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the Global Chinese Financial Forum (GCFF) Virtual Conference—Diversified Investing Strategies on November 5 at 1:45 p.m. Eastern Time.

Ocugen to Present at the GCFF Virtual Conference - Diversified Investing Strategies

MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on the importance of strategic partnerships in gene therapy including product consistency, identifying the right partner as well as providing examples of successful partnerships at the 4th Annual Gene Therapy for Rare Disorders Europe Conference from October 26-28, 2020 presented digitally.

CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference

MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.

Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

MALVERN, Pa., Sept.  29, 2020  (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will participate in a Virtual Fireside Chat during the Chardan Genetic Medicines Conference on October 6th at 9 a.m.

Ocugen to Participate in a Virtual Fireside Chat at the Chardan Genetic Medicines Conference

Probably because it's not a buzzworthy coronavirus stock, you might not hear much about OCGN stock but it still has strong upside potential.
The post Biotech Speculators Should Try a Small Position in Ocugen Stock appeared first on InvestorPlace.

Biotech Speculators Should Try a Small Position in Ocugen Stock

Ocugen continues to conduct at-the-market offerings to raise capital. But with a distant payoff, OCGN stock offers too much risk and not enough reward.

Don’t Be Deceived: There’s No Reason to Speculate on Ocugen

MALVERN, Pa., Sept.  16, 2020  (GLOBE NEWSWIRE) --  Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 1:40 p.m.

Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Because of the pandemic, OCGN stock attracts speculative interest. But it is not likely to pay off in the long-run
The post If the FDA Can’t Help Ocugen Stock, You Have to Wonder Who Can appeared first on InvestorPlace.

If the FDA Can’t Help Ocugen Stock, You Have to Wonder Who Can

In analyzing the science behind OCGN stock, the innovation is quite profound. However, it’s this very platform that is under serious scrutiny thanks to the coronavirus.

Why the Coronavirus May Have Disrupted Ocugen

OCGN stock isn't the next great biotech play, but savvy traders can limit its risk.
The post The Risk-Reward Ratio of Ocugen Stock Is Positive appeared first on InvestorPlace.

News for Ocugen, Inc. Stock (OCGN)